5 directorsName after signing inVisible after signing in and 4 others
Owners2 names in the annual accounts
27.67%Name after signing inVisible after signing in and 1 other
Documentsfilings and deeds
24-07-20267 days before the deadline
2025abbreviated format
Gross margin from €469,675 to €991,461Loss of €2.1mStaff from 8.4 FTE to 11.9 FTE1 director appointed, 1 resignation05-05Capital increase of €2,954,34013-03Registered office moved within Charleroi12-02
Lower net result than 89% of companies in research and development. The sector median is €423, over 343 companies.
Checked score
Checked score
The higher the Checked score (0 to 100), the smaller the chance that the company goes bankrupt within twelve months. That chance sets the band, from Critical to Excellent, and within the band how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
XXVisible after signing in
HiddenVisible after signing in
Bankruptcy probability within 12 months
Bankruptcy probability
It is the chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. At 0.2%, about 2 in 1,000 comparable companies go bankrupt. The higher it is, the shorter the payment term to agree.
XXVisible after signing in
Financial strength
Financial strength
Financial strength measures the balance sheet and the results with three figures out of 100 from the latest annual accounts: solvency, liquidity and profitability. It does not directly set the Checked score's band. How the company does against its sector peers on these and on growth does count for its place within the band.
XXVisible after signing in
XXVisible after signing in
XXVisible after signing in
Score breakdown
Visible after signing inVisible after signing in
Comparable companies, two years later
In July 2024, 224 companies had the same profile as Santero Therapeutics has now. Each dot is one company, two years later.
88.4%
were still trading
7.1%
stopped another way
4.0%
went bankrupt
Small
5 to 10 years old
solvency 30% or more
a loss of 10% of the balance sheet or more
Another 0.4% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
The companies in ten equal groups, from the lowest to the highest expected share
Group
Expected
Actual
1
0.2%
0.2%
2
0.3%
0.5%
3
0.5%
0.6%
4
0.7%
0.8%
5
0.9%
0.9%
6
1.3%
1.5%
7
1.6%
1.8%
8
1.8%
1.8%
9
2.9%
3.1%
10
5.6%
6.1%
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 224 companies, not a prediction for Santero Therapeutics. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit verdict
The credit verdict says how much credit you can give the company on open account. “Acceptable” means normal terms, “With conditions” means limiting the amount or the term. “Not advised” means asking for payment up front.
Visible after signing inVisible after signing in
Credit check for an amount and term of your choice
Name hiddenVisible after signing in 27.67%score XXVisible after signing inequity €24.6m (2025) · annual accounts 2025 of Name after signing inVisible after signing in
Name hiddenVisible after signing in 15.81%equity €11.45bn (2025) · annual accounts 2025 of Hidden nameVisible after signing in
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0765790155
New daily management delegateName after signing inVisible after signing in appointed, Name hiddenVisible after signing in resigned · Hidden nameVisible after signing in acts as permanent representative · Gazette deed
Name after signing inVisible after signing in and Name hiddenVisible after signing in act as permanent representatives
Board meeting of 01-12-2025 · Gazette deed
1 director appointed, 1 resignationHidden nameVisible after signing in resigns · Name after signing inVisible after signing in appointed · Name hiddenVisible after signing in acts as permanent representative · General meeting of 23-12-2024 · Gazette deed
Sector peers are the companies with the same activity (NACE code) and, where stated, the same size, that the company is compared with. A percentile says how many of them do worse.
These companies have the same main activity as Santero Therapeutics: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €1.8m and €10m, founded between 2019 and 2022.
Official details
Source: KBO
Status
Active since 29-03-2021Normal situation
Registered office
36 active companies are registered at this addressOf these, 3 started in the 12 months before 19 November 2026. Source: KBO register, as of 19 November 2026.
Santero Therapeutics files the abbreviated format. That format states no turnover. The gross margin rose from -€104,804 in 2021 to €991,461 in 2025.
In June 2023, five directors stepped down. In February 2026, the Official Gazette published the appointment of Name after signing inVisible after signing in as managing director.
What is the company number of Santero Therapeutics?
The company number of Santero Therapeutics is 0765.790.155. The VAT number is the same number with BE in front: BE 0765.790.155.
Where is Santero Therapeutics based?
The registered office is at Rue Clément Ader 10, 6041 Charleroi.Company details
What does Santero Therapeutics do?
According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
What is the legal form of Santero Therapeutics?
Santero Therapeutics is a private limited company (BV).
When was Santero Therapeutics founded?
Santero Therapeutics was founded on 29-03-2021.
Is Santero Therapeutics still active?
Yes, Santero Therapeutics is an active enterprise in the KBO register.
How many employees does Santero Therapeutics have?
Santero Therapeutics had an average of 11.9 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does Santero Therapeutics fall under?
In its 2025 annual accounts, Santero Therapeutics states joint committee 207 (White-collar workers in the chemical industry).
What is the turnover of Santero Therapeutics?
The turnover in financial year 2025 is about €2.4m. This figure is estimated from the gross margin of €991,461 and 2,136 comparable companies of the same size. It probably lies between €1.4m and €4.1m. It is a rough estimate.
Is Santero Therapeutics profitable?
In financial year 2025, Santero Therapeutics made a loss of €2.1m.
Where can I find the annual accounts of Santero Therapeutics?
Santero Therapeutics filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Santero Therapeutics due?
Santero Therapeutics must file the annual accounts for financial year 2026 by 31-07-2027.Timeline